Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.

ABSTRACT:

Background

There is conflicting evidence on the association between antipsychotic polypharmacy and metabolic syndrome in schizophrenia. We conducted a review of published systematic reviews to evaluate evidence on the association between metabolic syndrome (diabetes, hypertension, and hyperlipidaemia) and exposure to antipsychotic polypharmacy in schizophrenia.

Methods

We searched five electronic databases, complemented by reference screening, to find systematic reviews that investigated the association of antipsychotic polypharmacy in schizophrenia with hypertension, diabetes, or hyperlipidaemia. Selection of reviews, data extraction and review quality were conducted independently by two people and disagreements resolved by discussion. Results were synthesised narratively.<

SUBMITTER: Ijaz S 

PROVIDER: S-EPMC6122457 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature